Spearmark Health Limited 11064385 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is other manufacturing not elsewhere classified Digita Accounts Production Advanced 6.30.9574.0 true false 11064385 2024-04-01 2025-03-31 11064385 2025-03-31 11064385 bus:OrdinaryShareClass1 2025-03-31 11064385 core:CurrentFinancialInstruments 2025-03-31 11064385 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11064385 core:FurnitureFittingsToolsEquipment 2025-03-31 11064385 bus:SmallEntities 2024-04-01 2025-03-31 11064385 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 11064385 bus:FilletedAccounts 2024-04-01 2025-03-31 11064385 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11064385 bus:RegisteredOffice 2024-04-01 2025-03-31 11064385 bus:Director1 2024-04-01 2025-03-31 11064385 bus:Director2 2024-04-01 2025-03-31 11064385 bus:Director3 2024-04-01 2025-03-31 11064385 bus:Director4 2024-04-01 2025-03-31 11064385 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 11064385 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11064385 bus:Agent1 2024-04-01 2025-03-31 11064385 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 11064385 core:MotorVehicles 2024-04-01 2025-03-31 11064385 core:OfficeEquipment 2024-04-01 2025-03-31 11064385 core:PlantMachinery 2024-04-01 2025-03-31 11064385 1 2024-04-01 2025-03-31 11064385 countries:EnglandWales 2024-04-01 2025-03-31 11064385 2024-03-31 11064385 core:FurnitureFittingsToolsEquipment 2024-03-31 11064385 2023-04-01 2024-03-31 11064385 2024-03-31 11064385 bus:OrdinaryShareClass1 2024-03-31 11064385 core:CurrentFinancialInstruments 2024-03-31 11064385 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 11064385 core:FurnitureFittingsToolsEquipment 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 11064385

Spearmark Health Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Spearmark Health Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Spearmark Health Limited

Company Information

Directors

Mr Terence Anthony Bloom

Maureen Lucille Bloom

Mrs Sarah Doerfler

Mr Alexander Simon Bloom

Registered office

Flat 5 Palazzo House
43 Beech Hill
Barnet
EN4 0JW

Accountants

Kajaine Kafton LLP
Chartered Accountants42-46 Station Road
Edgware
HA8 7AB

 

Spearmark Health Limited

(Registration number: 11064385)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

163

3,016

Current assets

 

Stocks

5

27,290

19,533

Debtors

6

7,493

22,717

Cash at bank and in hand

 

2,234

5,284

 

37,017

47,534

Creditors: Amounts falling due within one year

7

(240,751)

(190,837)

Net current liabilities

 

(203,734)

(143,303)

Net liabilities

 

(203,571)

(140,287)

Capital and reserves

 

Called up share capital

8

100

100

Retained earnings

(203,671)

(140,387)

Shareholders' deficit

 

(203,571)

(140,287)

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 13 May 2025 and signed on its behalf by:
 

.........................................
Mr Terence Anthony Bloom
Director

 

Spearmark Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Flat 5 Palazzo House
43 Beech Hill
Barnet
EN4 0JW
England

These financial statements were authorised for issue by the Board on 13 May 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Spearmark Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant & Machinery

33% per annum

Motor Vehicles

33% per annum

Computer Equipment

33% per annum

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Spearmark Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2024 - 3).

 

Spearmark Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2024

82,423

82,423

At 31 March 2025

82,423

82,423

Depreciation

At 1 April 2024

79,409

79,409

Charge for the year

2,851

2,851

At 31 March 2025

82,260

82,260

Carrying amount

At 31 March 2025

163

163

At 31 March 2024

3,016

3,016

5

Stocks

2025
£

2024
£

Other inventories

27,290

19,533

6

Debtors

Current

2025
£

2024
£

Trade debtors

1,948

16,120

Prepayments

119

131

Other debtors

5,426

6,466

 

7,493

22,717

 

Spearmark Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Trade creditors

 

2,720

12,205

Taxation and social security

 

-

1,591

Other creditors

 

-

413

Accrued expenses

 

4,363

7,603

Directors current account

 

233,668

169,025

 

240,751

190,837

8

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary Share of £1 each

100

100

100

100

       

9

Related party transactions

Directors' remuneration

The directors' remuneration for the year was as follows:

2025
£

2024
£

Remuneration

-

100

10

 

The ultimate parent undertaking of the Company during the year was Droplet Health Limited, which is registered in England and Wales.

The registered office of Droplet Health Limited is 4 Harmsworth Way, London N20 8JU.